Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 'Adverse Reaction' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Adverse Reaction' found in 1 term [] and 6 definitions []
1 - 5 (of 7)     next
Result Pages : [1]  [2]
Searchterm 'Adverse Reaction' was also found in the following services: 
spacer
News  (2)  
 
Adverse Reaction
 
Any abnormal reaction of a patient to an examination or procedure, like for example claustrophobia or side effects of MRI contrast agents.
A claustrophobic attack is MRI scanner dependent and more rare with an open MRI. An adverse reaction with magnetic resonance imaging contrast medium is very infrequent. In general, adverse reactions increase with the quantity of contrast media (usual dose of paramagnetic contrast agents is 0.1 mmol/kg) and also with the osmolarity of the compound.
Most frequently encountered adverse reactions are heat sensation, dizziness, nausea, hypotension due to vasodilatation, which can progress to hypotensive shock and anaphylactic reactions.
See also MRI Safety, Contrast Enhanced MRI, Breast MRI, and Cardiac MR imaging.
Radiology-tip.comradSafety of Contrast Agents,  Anaphylactoid Reaction
spacer
Medical-Ultrasound-Imaging.comUltrasound Contrast Agent Safety
spacer
• For this and other aspects of MRI safety see our InfoSheet about MRI Safety.
• Patient-related information is collected in our MRI Patient Information.

 
• Share the entry 'Adverse Reaction':  Facebook  Twitter  LinkedIn  
 
• Related Searches:
    • Open MRI
    • Magnetohydrodynamic Effect
    • Drug Development and Approval Process (USA)
    • MRI Risks
    • Nerve Conductivity
 
Further Reading:
  Basics:
Questions and Answers on Gadolinium-Based Contrast Agents
Friday, 9 January 2009   by www.fda.gov    
Contrast Agents: Safety Profile
   by www.clinical-mri.com    
  News & More:
CT contrast reaction raises MRI contrast risk
Tuesday, 22 February 2022   by www.sciencedaily.com    
Searchterm 'Adverse Reaction' was also found in the following services: 
spacer
Radiology  (12) Open this link in a new windowUltrasound  (5) Open this link in a new window
ABLAVARâ„¢InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
ABLAVAR™ (formerly named Vasovistâ„¢) is a blood pool agent for magnetic resonance angiography (MRA), which opens new medical imaging possibilities in the evaluation of aortoiliac occlusive disease (AIOD) in patients with suspected peripheral vascular disease.
ABLAVARâ„¢ binds reversibly to blood albumin, providing imaging with high spatial resolution up to 1 hour after injection, due to its high relaxivity and to the long lasting increased signal intensity of blood.
As with other contrast media: the possibility of serious or life-threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory and/or cutaneous manifestations, should always be considered.

WARNING:
NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

See also Cardiovascular Imaging, Adverse Reaction, Molecular Imaging, and MRI Safety.
Drug Information and Specification
NAME OF COMPOUND
Diphenylcyclohexyl phosphodiester-Gd-DTPA, gadofosveset trisodium, MS-325
CENTRAL MOIETY
Gd2+
CONTRAST EFFECT
T1, predominantly positive enhancement
20-45 mmol-1sec-1, Bo=0,47T
PHARMACOKINETIC
Intravascular
825 mOsmol/kg H2O
CONCENTRATION
244 mg/mL, 0.25mmol/mL
DOSAGE
0.12 mL/kg, 0.03 mmol/kg
PREPARATION
ready to use
DEVELOPMENT STAGE
FDA approved
DISTRIBUTOR
See below
PRESENTATION
10 mL vials
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information
TERRITORY
TRADE NAME
DEVELOPMENT
STAGE
DISTRIBUTOR
EU
Approved
USA, Canada, Australia
ABLAVARâ„¢
Approved
spacer

• View the DATABASE results for 'ABLAVAR™' (3).Open this link in a new window


• View the NEWS results for 'ABLAVARâ„¢' (1).Open this link in a new window.
 
Further Reading:
  Basics:
Ablavar Prescribing Information
   by www.ablavar.com    
  News & More:
The first FDA-approved blood-pool MR agent offers additional time for imaging and possibly some new applications
Thursday, 1 July 2010   by www.radiologytoday.net    
MRI Safety Resources 
Safety Training - Safety Products - Guidance - Pregnancy - Pacemaker
 
Blood Brain BarrierInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
The brain tissue is provided with a tight endothelial layer on vessels that acts as a filter for substances that reach the brain through the blood stream. This filter is called the blood brain barrier.
The blood brain barrier is responsible for the absence of contrast agent enhancement in normal brain tissue after administration of the iodinated or paramagnetic contrast media used in brain MRI and computed tomography (CT) diagnostic. The absence of contrast uptake in normal tissue provides the basis for differentiation from pathological brain tissue, which is conversely characterized by a disruption of the blood brain barrier.

See also Contrast Enhanced MRI, MRI Safety, Adverse Reaction.
 
Images, Movies, Sliders:
 MRI Orbita T1  Open this link in a new window
 MRI Orbita T1 with Contrast  Open this link in a new window
 
spacer

• View the DATABASE results for 'Blood Brain Barrier' (7).Open this link in a new window

 
Further Reading:
  News & More:
Hyperosmolar blood-brain barrier opening using intra-arterial injection of hyperosmotic mannitol in mice under real-time MRI guidance
Monday, 13 December 2021   by www.nature.com    
Nanorobotic agents open the blood-brain barrier, offering hope for new brain treatments
Wednesday, 25 March 2015   by www.nanowerk.com    
Magnetic resonance-guided motorized transcranial ultrasound system for blood-brain barrier permeabilization along arbitrary trajectories in rodents
Thursday, 24 December 2015   by www.ncbi.nlm.nih.gov    
Searchterm 'Adverse Reaction' was also found in the following services: 
spacer
News  (2)  
 
Contrast AgentsForum -
related threadsInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Contrast agents are chemical substances introduced to the anatomical or functional region being imaged, to increase the differences between different tissues or between normal and abnormal tissue, by altering the relaxation times. MRI contrast agents are classified by the different changes in relaxation times after their injection.
•
Positive contrast agents cause a reduction in the T1 relaxation time (increased signal intensity on T1 weighted images). They (appearing bright on MRI) are typically small molecular weight compounds containing as their active element Gadolinium, Manganese, or Iron. All of these elements have unpaired electron spins in their outer shells and long relaxivities.
Some typical contrast agents as gadopentetate dimeglumine, gadoteridol, and gadoterate meglumine are utilized for the central nervous system and the complete body; mangafodipir trisodium is specially used for lesions of the liver and gadodiamide for the central nervous system.
•
Negative contrast agents (appearing predominantly dark on MRI) are small particulate aggregates often termed superparamagnetic iron oxide (SPIO). These agents produce predominantly spin spin relaxation effects (local field inhomogeneities), which results in shorter T1 and T2 relaxation times.
SPIO's and ultrasmall superparamagnetic iron oxides (USPIO) usually consist of a crystalline iron oxide core containing thousands of iron atoms and a shell of polymer, dextran, polyethyleneglycol, and produce very high T2 relaxivities. USPIOs smaller than 300 nm cause a substantial T1 relaxation. T2 weighted effects are predominant.
•
A special group of negative contrast agents (appearing dark on MRI) are perfluorocarbons (perfluorochemicals), because their presence excludes the hydrogen atoms responsible for the signal in MR imaging.

The design objectives for the next generation of MR contrast agents will likely focus on prolonging intravascular retention, improving tissue targeting, and accessing new contrast mechanisms. Macromolecular paramagnetic contrast agents are being tested worldwide. Preclinical data shows that these agents demonstrate great promise for improving the quality of MR angiography, and in quantificating capillary permeability and myocardial perfusion.
Ultrasmall superparamagnetic iron oxide (USPIO) particles have been evaluated in multicenter clinical trials for lymph node MR imaging and MR angiography, with the clinical impact under discussion. In addition, a wide variety of vector and carrier molecules, including antibodies, peptides, proteins, polysaccharides, liposomes, and cells have been developed to deliver magnetic labels to specific sites. Technical advances in MR imaging will further increase the efficacy and necessity of tissue-specific MRI contrast agents.

See also Adverse Reaction and Nephrogenic Systemic Fibrosis.

See also the related poll result: 'The development of contrast agents in MRI is'
 
Images, Movies, Sliders:
 Delayed Myocardial Contrast Enhancement from Infarct  Open this link in a new window
      

Courtesy of  Robert R. Edelman
 Left Circumflex Ischemia First-pass Contrast Enhancement  Open this link in a new window
 MR Colonography Gadolinium per Rectum  Open this link in a new window
      

Courtesy of  Robert R. Edelman
 CE MRA of the Aorta  Open this link in a new window
    
SlidersSliders Overview

 
Radiology-tip.comradContrast Agents,  Safety of Contrast Agents
spacer
Medical-Ultrasound-Imaging.comUltrasound Contrast Agents,  Ultrasound Contrast Agent Safety
spacer

• View the DATABASE results for 'Contrast Agents' (122).Open this link in a new window


• View the NEWS results for 'Contrast Agents' (25).Open this link in a new window.
 
Further Reading:
  Basics:
Analysis of MRI contrast agents
Thursday, 17 November 2022   by www.sciencedaily.com    
New guidelines urge caution on use of contrast agents during MR scans
Tuesday, 8 August 2017   by www.dotmed.com    
New Study Sheds Light on Safety of Gadolinium-Based Contrast Agents
Wednesday, 29 November 2017   by www.empr.com    
A safer approach for diagnostic medical imaging
Monday, 29 September 2014   by www.eurekalert.org    
Manganese-based MRI contrast agents: past, present and future
Friday, 4 November 2011   by www.ncbi.nlm.nih.gov    
  News & More:
Brain imaging method may aid mild traumatic brain injury diagnosis
Tuesday, 16 January 2024   by parkinsonsnewstoday.com    
A Targeted Multi-Crystalline Manganese Oxide as a Tumor-Selective Nano-Sized MRI Contrast Agent for Early and Accurate Diagnosis of Tumors
Thursday, 18 January 2024   by www.dovepress.com    
FDA Approves Gadopiclenol for Contrast-Enhanced Magnetic Resonance Imaging
Tuesday, 27 September 2022   by www.pharmacytimes.com    
How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol
Saturday, 5 February 2022   by www.ncbi.nlm.nih.gov    
Estimation of Contrast Agent Concentration in DCE-MRI Using 2 Flip Angles
Tuesday, 11 January 2022   by pubmed.ncbi.nlm.nih.gov    
Manganese enhanced MRI provides more accurate details of heart function after a heart attack
Tuesday, 11 May 2021   by www.news-medical.net    
Gadopiclenol: positive results for Phase III clinical trials
Monday, 29 March 2021   by www.pharmiweb.co    
Gadolinium-Based Contrast Agents Hypersensitivity: A Case Series
Friday, 4 December 2020   by www.dovepress.com    
Polysaccharide-Core Contrast Agent as Gadolinium Alternative for Vascular MR
Monday, 8 March 2021   by www.diagnosticimaging.com    
Water-based non-toxic MRI contrast agents
Monday, 11 May 2020   by chemistrycommunity.nature.com    
New method to detect early-stage cancer identified by Georgia State, Emory research team
Friday, 7 February 2020   by www.eurekalert.org    
Researchers Brighten Path for Creating New Type of MRI Contrast Agent
Friday, 7 February 2020   by www.newswise.com    
Manganese-based MRI contrast agent may be safer alternative to gadolinium-based agents
Wednesday, 15 November 2017   by www.eurekalert.org    
Sodium MRI May Show Biomarker for Migraine
Friday, 1 December 2017   by psychcentral.com    
A natural boost for MRI scans
Monday, 21 October 2013   by www.eurekalert.org    
For MRI, time is of the essence A new generation of contrast agents could make for faster and more accurate imaging
Tuesday, 28 June 2011   by scienceline.org    
Searchterm 'Adverse Reaction' was also found in the following services: 
spacer
Radiology  (12) Open this link in a new windowUltrasound  (5) Open this link in a new window
Ionic Intravenous Contrast AgentsInfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Intravenous contrast agents used in MRI are distributed in the extracellular spaces of the body before being excreted. In this sense they are similar to iodinated X-ray contrast media. However, contrast agents used for MRI are quite different from conventional radiographic contrast media in structure and function and there is no known cross sensitivity between these types of contrast agents. Common MRI contrast agents use metal ions (e.g., gadolinium or manganese) complexed with organic molecules.
Gd-DTPA, an ionic linear molecule complex (gadopentetate dimeglumine) was the first marketed MRI contrast agent. Although the osmolality of this substances can be relatively high (up to 1940 mOsm/kg H2O) compared with plasma, adverse reactions and side effects are very rare. The used doses are smaller compared with radiographic contrast media.

See also Nonionic Intravenous Contrast Agents, Dotarem®, and Magnevist®.
 
Images, Movies, Sliders:
 Breast MRI Images T1 Pre - Post Contrast  Open this link in a new window
      
 
spacer

• View the DATABASE results for 'Ionic Intravenous Contrast Agents' (5).Open this link in a new window

 
Further Reading:
  Basics:
FDA Approves First Macrocyclic and Ionic Gadolinium-Contrast Agent for MRI
Friday, 22 March 2013   by www.itnonline.com    
  News & More:
Spurious Hypocalcemia After Omniscan- or OptiMARK-Enhanced Magnetic Resonance Imaging: An Algorithm for Minimizing a False-Positive Laboratory Value
   by arpa.allenpress.com    
MRI Resources 
Most Wanted - Blood Flow Imaging - PACS - Manufacturers - Breast Implant - Claustrophobia
 
     1 - 5 (of 7)     next
Result Pages : [1]  [2]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



New acceleration techniques will :
reduce scan times 
cause artifacts 
increase expenses 
be useful if you have a lot of experience 
doesn't do much 
never heard of 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 29 March 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]